Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.77 |
| ▸ | APP | P05067 | 3/20 | 0.73 |
| ▸ | TTR | P02766 | 2/20 | 0.73 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | FDPS | P14324 | 1/20 | 0.67 |
| ▸ | BACE1 | P56817 | 4/20 | 0.66 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.63 |
| ▸ | TUBB | P07437 | 1/20 | 0.63 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.63 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.63 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.63 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.63 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.63 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.63 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.63 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.63 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.63 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9397987 | 1.00 | EPHX2 (0.77) | EPHX2APPTTRPTPN1MAPT | |
| Methyl Cis-Ferulate SCHEMBL510492 | 0.87 | EPHX2 (1.00) | EPHX2APPTTRPTPN1MAPT | |
| SCHEMBL5599057 | 0.87 | MAPT (0.89) | APPMAPTBACE1KDM4EALDH1A1 | |
| Methyl Cis-Ferulate SCHEMBL2085720 | 0.87 | EPHX2 (1.00) | EPHX2APPTTRPTPN1MAPT | |
| Methyl Cis-Ferulate SCHEMBL29406729 | 0.87 | EPHX2 (1.00) | EPHX2APPTTRPTPN1MAPT | |
| SCHEMBL2622437 | 0.87 | MAPT (0.89) | APPMAPTBACE1KDM4EALDH1A1 | |
| SCHEMBL2744728 | 0.87 | NFKB1 (0.76) | APPMAPTBACE1TUBB1TUBB4A | |
| SCHEMBL2744733 | 0.87 | NFKB1 (0.76) | APPMAPTBACE1TUBB1TUBB4A | |
| Methyl Cis-3,4-Dimethoxycinnamate SCHEMBL2411956 | 0.87 | FDPS (0.80) | EPHX2APPTTRMAPTFDPS | |
| Methyl Cis-3,4-Dimethoxycinnamate SCHEMBL2411955 | 0.87 | FDPS (0.80) | EPHX2APPTTRMAPTFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117792-A1 | USE OF SUBSTITUTED CINNAMIC ACID ESTERS AS STABILISERS FOR ORGANIC MATERIALS, STABILISED ORGANIC MATERIAL, METHOD FOR STABILISING ORGANIC MATERIALS AND SPECIFIC CINNAMIC ACID ESTERS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-04-20 | — | — | US | disclosed |
| US-20210346331-A1 | TRPV4 ACTIVITY INHIBITOR | KAO CORPORATION (JP) | 2021-11-11 | — | — | US | disclosed |
| WO-2021191078-A1 | USE OF SUBSTITUTED CINNAMIC ACID ESTERS AS STABILISERS FOR ORGANIC MATERIALS, STABILISED ORGANIC MATERIAL, METHOD FOR STABILISING ORGANIC MATERIALS AND SPECIFIC CINAMIC ACID ESTERS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2021-09-30 | — | — | WO | disclosed |
| US-20070161704-A1 | Pharmaceutical composition useful for treating chronic myeloid leukemia | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-07-12 | — | — | US | disclosed |
| US-20070161704-A1 | Pharmaceutical composition useful for treating chronic myeloid leukemia | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-07-12 | — | — | US | disclosed |
| WO-2004063169-A1 | HYDROXAMID ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-07-29 | — | — | WO | disclosed |
| US-5344845-A | Methyl 4(4-acetoxy-3-methoxycinnamanide and salts as an immunosuppressive drug for allergic reactions | TSUMURA & CO. (JP) | 1994-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346331-A1 | TRPV4 ACTIVITY INHIBITOR | TRPV4, TRPV5, TRPM4 | EPHX2 3814/4885APP 4209/4885TTR 4609/4885 |
| US-20070161704-A1 | Pharmaceutical composition useful for treating chronic myeloid leukemia | ABL1, CLIC1, HCLS1 | EPHX2 2928/4885APP 4835/4885TTR 2683/4885 |
| US-20230117792-A1 | USE OF SUBSTITUTED CINNAMIC ACID ESTERS AS STABILISERS FOR ORGANIC MATERIALS, STABILISED ORGANIC MATERIAL, METHOD FOR STABILISING ORGANIC MATERIALS AND SPECIFIC CINNAMIC ACID ESTERS | TECR, NISCH, CAD | EPHX2 247/4885APP 643/4885TTR 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.